With great scientific discoveries come great dilemmas. And one such dilemma that dominates the medical zeitgeist relates to weight-loss injections such as Wegovy, Ozempic, Mounjaro and Zepbound. Namely, who really needs drugs like these – and who should have to pay for them?
It’s a debate I’m more familiar with than most because I am a drugs research specialist and until 2015 was a director at Novo Nordisk, the pharmaceutical company that makes Wegovy and Ozempic.
In the 15 years I worked there, I led and executed research on blood sugar, type 2 diabetes, gut hormones and inflammation – and, along with
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.